Results 261 to 270 of about 440,409 (317)
Differences in metabolic adaptations during mid and late pregnancy: a comparative cohort study between Rwanda and Germany. [PDF]
Amberbir A+13 more
europepmc +1 more source
Correlation of fibrinogen levels with acute myocardial infarction risk in the Chinese Han population. [PDF]
Xu JP+8 more
europepmc +1 more source
Sex Differences in the Association Between Lipoprotein(a) and Cardiovascular Outcomes: The MGB Lp(a) Registry. [PDF]
Kaur G+12 more
europepmc +1 more source
Optimizing treatment of cardiovascular risk factors in cerebral small vessel disease using genetics. [PDF]
Koohi F+5 more
europepmc +1 more source
The interactions of Lipoprotein(a) with common cardiovascular risk factors in cardiovascular disease risk: evidence based on the UK Biobank. [PDF]
Ao L+4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Lipoproteins and Lipoprotein Metabolism
1975The plasma lipoproteins provide the body with a transport system for the otherwise insoluble lipids. All lipids except for free fatty acids and lysolecithin, circulate in plasma from their site of origin to their site of utilization in association with these lipid-protein complexes, the lipoproteins. In healthy humans, more than 100 g of triglycerides,
S. Eisenberg, R. I. Levy
openaire +2 more sources
Endocrinology and Metabolism Clinics of North America, 2015
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients ...
Patrick M, Moriarty, Linda, Hemphill
openaire +3 more sources
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients ...
Patrick M, Moriarty, Linda, Hemphill
openaire +3 more sources